Tamtam Try Tamtam free
GE HealthCare logo

GE HealthCare account plan

Medical technology solutions innovator

At a glance

GE HealthCare sells imaging, ultrasound, monitoring and contrast agents in over 160 countries: $20,625 million FY2025 revenue, ~54,000 colleagues.

GE HealthCare Technologies Inc. (Nasdaq: GEHC), headquartered in Chicago and spun off from General Electric on January 3, 2023, sells medical devices, consumables, services and AI-enabled cloud and software to hospitals, health systems and researchers in over 160 countries. Its portfolio spans CT, MR, molecular imaging, X-ray, ultrasound and interventional systems, patient monitoring and anesthesia, and contrast media and radiopharmaceuticals. FY2025 total revenues were $20,625 million (+4.8% reported, +3.5% organic), with operating income of $2,763 million, net income attributable of $2,084 million and free cash flow of $1,505 million. It has approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers, and manufactures in 44 facilities across 17 countries.

Business units

Strategic priorities

D3 growth strategy
Growth is framed as D3, combining smart devices and drugs, a disease-state focus and digital capabilities, particularly AI, executed through the Heartbeat lean business system.
New product cycle
New products such as Photonova Spectra photon-counting CT (shipments from early 2027), Total Body PET, SIGNA Bolt 3T MR and Vivid Pioneer ultrasound are meant to lift growth from the 3%-4% lane to mid-single digits; they are still under 20% of order value.
Grow Pharmaceutical Diagnostics
Management says PDx is in "a renaissance window"; the target for the Flyrcado PET tracer is $500 million or more in annual revenue by 2028, and the contrast market is expected to double over the next decade.
Medium-term margin and growth targets
Medium-term targets are mid-single-digit organic growth, a high-teens to 20% adjusted EBIT margin and 90% free cash flow conversion; the CEO says the 17-20 margin range remains on track.
Fix and review Patient Care Solutions
The first job is to get PCS supply and fulfillment back on track, then decide on options including continued ownership or a sale, with an update expected around February.
Stabilise China
China is still modeled down in 2026; the company has localised most in-China-for-China manufacturing, with another 10% to go, and set up a provincial government affairs group to address volume-based procurement.

Latest results

In Q2 2026 total revenues were $5,295 million, up 5.7% reported and 3.5% organic, led by PDx and AIS while PCS fell 13.3%. Organic orders grew 11.1%, book-to-bill was 1.15 times and backlog reached a record $23.9 billion. Adjusted EBIT was $750 million (14.2% margin, down 40 bps) as PCS and inflation in memory chips, oil and freight weighed; Adjusted EPS was $1.13 vs $1.06. IEEPA tariff refunds of $107 million were received in the quarter. Guidance for 2026 was reaffirmed: organic growth of 3.0% to 4.0%, Adjusted EBIT margin of 15.4% to 15.7%, Adjusted EPS of $4.80 to $5.00 and free cash flow of approximately $1.6 billion.

Investments and deals

Intelerad acquisition
Acquired March 18, 2026 for approximately $2,293 million in cash; a cloud-first medical imaging software and workflow company with a significant outpatient presence, now part of AIS.
Nihon Medi-Physics
The remaining 50% of the Japanese radiopharmaceutical manufacturer was bought for $271 million, making it wholly owned on March 31, 2025.
AI imaging tuck-ins
icometrix (AI brain imaging) was acquired for approximately $98 million plus up to $35 million earn-out in November 2025, alongside Spectronic Medical AB.
R&D and capacity capex
FY2025 R&D spending was $1,260 million and capex $482 million; capital priorities remain organic investment first, then tuck-in M&A, then buybacks.

Challenges and risks

Tariffs and cost inflation
Tariffs cut operating income by approximately $245 million in 2025, and 2026 guidance absorbs approximately $250 million of inflation from memory chips, oil and freight linked partly to the Middle East conflict.
Patient Care Solutions operations
PCS revenue fell 13.5% organically in Q2 2026 with negative EBIT, driven by supply of critical components, end-of-life components and fulfillment problems.
China competition and procurement
China region revenue fell 4.6% in FY2025 amid local competition and volume-based procurement, which the company models will ultimately be over half of the market.
Supply chain inputs
The business depends on helium, iodine and rare earth minerals, and China tightened rare-earth export controls in 2025.
Debt and pension load
Total debt was $10,093 million at June 30, 2026, and pension plans carry a total funded deficit of $4,365 million.

What leadership says

“We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products.”

Peter Arduini, President and CEO · GE HealthCare second quarter 2026 earnings release, 2026-07-29

“while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value.”

Peter Arduini, President and CEO · On Patient Care Solutions, Q2 2026 earnings release, 2026-07-29

“this is the best lineup GE HealthCare has ever had, period.”

Peter Arduini, President and CEO · On vascular products, Wells Fargo 21st Annual Healthcare Conference, 2026-09-09

“we're increasingly confident in the $500 million+ by 2028.”

Jay Saccaro, then VP and CFO · On Flyrcado, Jefferies Global Healthcare Conference, 2026-06-03

Where a supplier can help

Component supply and manufacturing for PCS
Tied to the Patient Care Solutions challenge: suppliers of critical electronic components, redesign of end-of-life parts or contract manufacturing can address the supply and fulfillment issues behind the decline.
Logistics and input-cost mitigation
Tied to the tariffs and inflation challenge: freight optimisation, alternative sourcing of memory chips and rare earths, and trade-compliance services fit an inflation load of approximately $250 million.
Radiopharmacy delivery and workflow
Tied to the PDx growth priority: Flyrcado adoption depends on radiopharmacy delivery reliability and clinic workflow, so specialised logistics and scheduling tools are relevant.
Software and AI integration
Tied to the D3 strategy and the Intelerad acquisition: cloud infrastructure, data integration and AI tooling partners can support imaging software and internal productivity work with agents.
Local sourcing in China
Tied to the China priority: local suppliers and manufacturing partners can help complete the remaining localisation needed to compete under volume-based procurement.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like GE HealthCare?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about GE HealthCare

What does GE HealthCare do?

GE HealthCare sells medical imaging and ultrasound systems, patient monitoring and anesthesia equipment, contrast media and radiopharmaceuticals, services and AI-enabled software to hospitals, health systems and researchers in over 160 countries.

What is GE HealthCare's revenue?

Total revenues were $20,625 million in FY2025, up 4.8% reported. Q2 2026 revenues were $5,295 million, up 5.7%.

How many employees does GE HealthCare have?

Approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers.

Who leads GE HealthCare?

Peter Arduini has been President and CEO since the spin-off. CFO Jay Saccaro left in 2026; George Newcomb served as interim CFO and new CFO Bill Grogan was due to join in mid-September 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)